Related Experiment Videos
p53 mutations in larynx cancer
L F Zhang1, K Hemminki, K Szyfter
1Center for Nutrition and Toxicology, Karolinska Institute, Huddinge, Sweden.
Carcinogenesis
|December 1, 1994
Summary
This study analyzed p53 gene mutations in larynx cancer patients, finding specific mutations linked to smoking. These findings contribute to understanding larynx cancer development and potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Larynx cancer is strongly linked to environmental factors like tobacco smoking and alcohol consumption.
- The p53 tumor suppressor gene plays a critical role in cellular response to DNA damage and is frequently mutated in various cancers.
Purpose of the Study:
- To investigate the spectrum of p53 gene mutations in fresh tumor samples from larynx cancer patients.
- To correlate observed p53 mutations with known risk factors such as smoking.
Main Methods:
- Analysis of p53 gene mutations using single-strand conformation polymorphism (SSCP) and direct DNA sequencing.
- Focus on exons 5-8 of the p53 gene, a region frequently involved in cancer-related mutations.
- Examination of 40 fresh tumor samples from larynx cancer patients.
Main Results:
- Mutations in the p53 gene were identified in 13 out of 40 (32.5%) larynx cancer samples.
- A total of six transitions and seven transversions were detected, including four T to A transversions.
- Specific codons (205, 248, 246) showed recurrent mutations. Notably, 46% of mutations were typical smoking-associated mutations (G to T, G to A, C to T).
- Over half (54%) of the mutations occurred within a known hotspot region (codons 238-248).
Conclusions:
- The study confirms the presence and characterizes the types of p53 gene mutations in larynx cancer.
- Observed mutation patterns suggest a significant contribution of smoking-induced DNA damage to larynx tumorigenesis.
- Understanding these molecular alterations can aid in developing targeted therapies and preventative strategies for larynx cancer.